PATENT CLAIM ANALYSIS

Application Number: 16239222
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["424", "488000"]

Abstract:
This disclosure relates to extended release oral dosage forms comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing a high water-soluble, high dose drug. The dosage forms have alcohol resistance and may also have crush resistance.

Claim (Index 14):
The dosage form of  claim 1 , wherein the high water-soluble, high dose drug is selected from acamprosate calcium, aceglutamide aluminum, acetazolamide sodium, acetohydroxamic acid, aliskiren fumarate, aminocaproic acid, aminophylline, amitriptyline HCl, amitriptyline HCl, balsalazide disodium dehydrate, benzphetamine HCl, buflomedil HCl, calcium acetate anhydrous, celiprolol HCl, chloroquine phosphate, diltiazem HCl, diphylline, disopyramide phosphate, divalproex sodium, dolasetron mesylate monohydrate, emtricitabine, eperisone HCl, estramustine sodium phosphate anhydrous, ethosuximide, etidronate disodium, famciclovir, flucloxacillin sodium hydrate, fudosteine, gabapentin, gemifloxacin mesylate, hydroxychloroquine sulfate, hydroxyurea, hydroxyzine HCl, levamisole HCl, levocamitine, losartan potassium, metformin HCl, methenamine hippurate, metoprolol succinate, mexiletine HCl, miglustat, milnacipran HCl, molindone HCl, naftidrofuryl oxalate, naltrexone HCl, orphenadrine HCl, oseltamivir phosphate, oseltamivir phosphate, oxprenolol HCl, pantoprazole sodium, penicillamine, phenelzine sulfate, piracetam, potassium bicarbonate, KCl, pregabalin, pseudoephedrine HCl, pyridostigmine bromide, quinapril HCl, rimantadine HCl, sotalol HCl, tacrine HCl, thioridazine HCl, ticlopidine HCl, ticlopidine HCl, tolmetin sodium anhydrous, tranexamic acid, trapidil, trientine HCl, tripelennamine HCl, venlafaxine, zinc acetate, abacavir sulfate, acebutolol HCl, bacampicillin HCl, benazepril HCl, beta-alanine, bupropion HBr, carbenicillin indanyl sodium chlordiazepoxide HCl, dantrolene sodium, desipramine HCl, desvenlafaxine succinate, dicyclomine HCl, flecamide acetate, hidrosmin, hydralazine HCl, labetalol HCl, lamivudine, 1-glutamine, lisdexamfetamine dimesylate, lisinopril dehydrate, loxapine succinate, miglitol, moracizine HCl, moxisylyte HCl, nortriptyline HCl, olsalazine sodium, ozagrel HCl, pentoxifylline, procarbazine, procarbazine HCl, raltegravir potassium, sitagliptin phosphate, sitaxsentan sodium, stavudine, strontium ranelate, tenofovir disoproxil fumarate, treosulfan, trimethobenzamide HCl, valacyclovir HCl, valganciclovir HCl, verapamil HCl, vildagliptin, aclatonium napadisilate, betaine, cevimeline HCl hydrate, chlorpromazine HCl, cysteamine bitartrate, didanosine, doxylamine succinate, fosfomycin trometamol, indinavir sulfate, itopride HCl, levetiracetam, lymecycline, maraviroc, mebeverine HCl, melperone HCl, meperidine HCl, meptazinol HCl, methenamine mandelate, metoprolol tartrate, paromomycin sulfate, procainamide HCl, ranitidine HCl, sodium oxybate, sodium valproate, tiapride HCl, venlafaxine HCl, vildagliptin, procaine HCl, sitaxsentan sodium and vigabatrin.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 99.0
- Lexical Diversity: 1.27778
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14296572', '13721128', '14527215', '14539231', '15210760']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8016185689425477
- 35 USC 102 Novelty (BERT): 0.5394177369709527
- Combined Prediction Score: 0.7753984857453883
- Mean Citation Score: 287.088994
- Max Citation Score: 368.59885
- Similarity Product: 270.6461037041545

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test